Skip to main content

Inbrija News

AAN: Tavapadon as Adjunct to Levodopa Ups Daily ON Time in Parkinson Disease

TUESDAY, April 8, 2025 – For patients with Parkinson disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist tavapadon as an adjunct to levodopa increases...

Early Research Points to Possible New Parkinson's Drug

THURSDAY, Dec. 19, 2024 – Parkinson's is a relentless disease for which few treatments, and no real cure, exists. Now, researchers say they are on the trail of a potential new therapy for the...

FDA Approves Inbrija (levodopa inhalation powder) for Intermittent Treatment of OFF Episodes in People with Parkinson’s Disease

ARDSLEY, N.Y.--(BUSINESS WIRE) December 21, 2018 --Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration approved Inbrija™ for intermittent treatment of OFF episodes in ...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Parkinson's Disease

Inbrija patient information at Drugs.com